Nothing Special   »   [go: up one dir, main page]

EA201300116A1 - Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком - Google Patents

Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком

Info

Publication number
EA201300116A1
EA201300116A1 EA201300116A EA201300116A EA201300116A1 EA 201300116 A1 EA201300116 A1 EA 201300116A1 EA 201300116 A EA201300116 A EA 201300116A EA 201300116 A EA201300116 A EA 201300116A EA 201300116 A1 EA201300116 A1 EA 201300116A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activin
bone growth
application
cancer patients
stimulate bone
Prior art date
Application number
EA201300116A
Other languages
English (en)
Other versions
EA025371B1 (ru
Inventor
Джон НОПФ
Джасбир СИХРА
Равиндра КУМАР
Original Assignee
Акселерон Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акселерон Фарма Инк. filed Critical Акселерон Фарма Инк.
Publication of EA201300116A1 publication Critical patent/EA201300116A1/ru
Publication of EA025371B1 publication Critical patent/EA025371B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/02—Processing of mobility data, e.g. registration information at HLR [Home Location Register] or VLR [Visitor Location Register]; Transfer of mobility data, e.g. between HLR, VLR or external networks
    • H04W8/08—Mobility data transfer
    • H04W8/082—Mobility data transfer for traffic bypassing of mobility servers, e.g. location registers, home PLMNs or home agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W40/00—Communication routing or communication path finding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W80/00—Wireless network protocols or protocol adaptations to wireless operation
    • H04W80/04—Network layer protocols, e.g. mobile IP [Internet Protocol]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W84/00—Network topologies
    • H04W84/18—Self-organising networks, e.g. ad-hoc networks or sensor networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L2212/00—Encapsulation of packets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)

Abstract

В конкретных аспектах настоящее изобретение относится к композициям и способам для стимуляции роста кости и увеличения плотности кости, а также для лечения множественной миеломы.
EA201300116A 2007-02-09 2008-02-01 АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ EA025371B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90058007P 2007-02-09 2007-02-09
US93276207P 2007-05-31 2007-05-31
US93736507P 2007-06-26 2007-06-26
US52807P 2007-10-25 2007-10-25

Publications (2)

Publication Number Publication Date
EA201300116A1 true EA201300116A1 (ru) 2013-09-30
EA025371B1 EA025371B1 (ru) 2016-12-30

Family

ID=39690668

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200970747A EA018221B1 (ru) 2007-02-09 2008-02-01 АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
EA201690994A EA201690994A1 (ru) 2007-02-09 2008-02-01 Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
EA201300116A EA025371B1 (ru) 2007-02-09 2008-02-01 АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA200970747A EA018221B1 (ru) 2007-02-09 2008-02-01 АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
EA201690994A EA201690994A1 (ru) 2007-02-09 2008-02-01 Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком

Country Status (25)

Country Link
US (4) US8173601B2 (ru)
EP (3) EP2484372A1 (ru)
JP (6) JP5574711B2 (ru)
KR (7) KR20190026047A (ru)
CN (3) CN104548056B (ru)
AR (1) AR065289A1 (ru)
AU (1) AU2008216896B2 (ru)
BR (1) BRPI0807506B1 (ru)
CA (3) CA2913992C (ru)
CY (1) CY1113963T1 (ru)
DK (1) DK2120999T3 (ru)
EA (3) EA018221B1 (ru)
ES (2) ES2756725T3 (ru)
HK (1) HK1137366A1 (ru)
HR (1) HRP20120947T1 (ru)
IL (3) IL200242B (ru)
ME (1) ME02333B (ru)
MX (2) MX368173B (ru)
PL (1) PL2120999T3 (ru)
PT (1) PT2120999E (ru)
RS (1) RS52535B (ru)
SI (1) SI2120999T1 (ru)
TR (1) TR200906329T1 (ru)
TW (7) TWI606062B (ru)
WO (1) WO2008100384A2 (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN103432568A (zh) 2005-11-23 2013-12-11 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
EP3320911B1 (en) 2006-12-18 2021-12-01 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TW201940502A (zh) * 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
US7960343B2 (en) * 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
DK2318028T3 (da) 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
CA2729100C (en) * 2008-06-26 2018-01-02 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
CN104840944A (zh) 2009-06-08 2015-08-19 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
AU2010292203A1 (en) * 2009-09-09 2012-04-12 Acceleron Pharma Inc. ActRIIb antagonists and dosing and uses thereof
US20110129469A1 (en) * 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
ES2658292T3 (es) * 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
KR20120115602A (ko) 2010-01-26 2012-10-18 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 골 관련 암의 치료
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
MX2015009264A (es) 2013-01-18 2016-03-31 Biomeme Inc Dispositivo analitico.
CN105229028B (zh) * 2013-03-20 2019-11-08 建新公司 用于治疗成骨不全的方法
JP2015159766A (ja) * 2014-02-27 2015-09-07 国立大学法人京都大学 クッシング症候群の検査方法、検査用バイオマーカー及び治療剤
ES2845650T3 (es) 2014-04-18 2021-07-27 Acceleron Pharma Inc Procedimientos para aumentar los niveles de glóbulos rojos y tratar la drepanocitosis
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
AU2016359695A1 (en) * 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
HUE054228T2 (hu) * 2016-07-15 2021-08-30 Acceleron Pharma Inc Használható actriia polipeptideket tartalmazó összetételek a pulmonalis hypertónia kezelésében történõ alkalmazásra
CN110430890B (zh) 2016-11-10 2024-09-10 科乐斯疗法公司 激活素受体iia型变体及其使用方法
GB201620119D0 (en) 2016-11-29 2017-01-11 Pharmafox Therapeutics Ag Compounds
CN110494155A (zh) * 2017-02-01 2019-11-22 阿塞勒隆制药公司 用于提高免疫活性的TGFβ和ActRII拮抗剂
CN110461359A (zh) 2017-03-24 2019-11-15 诺华股份有限公司 用于预防和治疗心脏病的方法
JP7293236B2 (ja) 2017-09-15 2023-06-19 バイオミーム インコーポレイテッド 自動試料処理のための方法およびシステム
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
EP3827837A4 (en) * 2018-07-24 2022-05-04 Good T Cells, Inc. COMPOSITION FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES
JP7483745B2 (ja) 2019-03-21 2024-05-15 バイオミーム インコーポレイテッド 多機能性分析デバイス
US20230132689A1 (en) 2020-03-31 2023-05-04 Cell Exosome Therapeutics Inc. Cell preservation method
JP2023545631A (ja) 2020-09-18 2023-10-31 バイオミーム，インコーポレイテッド 試料を分析するための運搬可能デバイスおよび方法

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
EP0548276A4 (en) 1990-09-13 1993-12-29 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ES2127757T3 (es) 1991-06-25 1999-05-01 Genetics Inst Composiciones bmp-9.
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP0679163A4 (en) 1993-01-12 1997-07-16 Univ Johns Hopkins Med FACTOR-3 OF GROWTH AND DIFFERENTIATION.
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
CA2174098C (en) 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
WO1996032503A1 (en) 1995-04-11 1996-10-17 The General Hospital Corporation Reverse two-hybrid systems
EP0771873A3 (en) * 1995-10-27 1998-03-04 Takeda Chemical Industries, Ltd. Neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US20050244867A1 (en) * 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
US6004780A (en) * 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
PL189756B1 (pl) 1996-10-25 2005-09-30 Searle & Co Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
CA2297489A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
JP2001513982A (ja) 1997-08-29 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド フォリスタチン−３
US6953662B2 (en) * 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
RU2221809C2 (ru) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU765584B2 (en) 1998-09-17 2003-09-25 Eli Lilly And Company Protein formulations
US6656708B1 (en) * 1998-09-22 2003-12-02 Long Yu Human growth differentiation factor encoding sequence and polypeptide encoded by such DNA sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) * 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN1163262C (zh) * 1999-04-01 2004-08-25 上海益众生物技术有限公司 成骨生长肽药物组合物及制备方法和应用
WO2000062809A1 (fr) 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de proliferation cellulaire pour tumeurs androgeno-independantes
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
MXPA02004671A (es) 1999-11-12 2004-09-10 Maxygen Holdings Ltd Conjugados de interferon gamma.
ATE319470T1 (de) 1999-12-15 2006-03-15 Res Dev Foundation Betaglycan als ein inhibin rezeptor und dessen verwendung
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
WO2002008277A2 (en) 2000-07-19 2002-01-31 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
EP1356075A4 (en) 2000-10-16 2005-04-13 Compound Therapeutics Inc PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
AU2002225670B2 (en) 2000-11-20 2006-05-11 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
EP1370287A2 (en) 2000-12-01 2003-12-17 Wyeth Method and composition for modulating bone growth
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
EP1369130A1 (en) 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
JP2004535182A (ja) 2001-05-24 2004-11-25 ザイモジェネティクス，インコーポレイティド Ｔａｃｉ−免疫グロブリン融合タンパク質
WO2002094864A2 (en) * 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
JP2003012699A (ja) 2001-07-04 2003-01-15 Japan Science & Technology Corp 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
ATE448481T1 (de) 2001-07-17 2009-11-15 Teijin Ltd Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoff
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
JP2006506943A (ja) 2002-02-11 2006-03-02 ジェネンテック・インコーポレーテッド 抗原結合速度の大きい抗体変異体
BR0307907A2 (pt) * 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
WO2003087162A2 (en) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
EP1534731A4 (en) 2002-08-16 2006-05-17 Wyeth Corp APPLICABLE TO BMP-2 STROGENIC ELEMENT AND METHOD FOR THE APPLICATION THEREOF
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
ZA200506246B (en) 2003-02-07 2006-12-27 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
US20040197828A1 (en) * 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
EP1706428B1 (en) 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
US7625867B2 (en) * 2004-03-26 2009-12-01 Acceleron Pharma Inc. BMP-3 propeptides and related methods
WO2005097825A2 (en) 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
CA2567810A1 (en) * 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
WO2006002387A2 (en) 2004-06-24 2006-01-05 Acceleron Pharma Inc. Gdf3 propeptides and related methods
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
US8617815B2 (en) 2004-08-05 2013-12-31 The Regents Of The University Of California Molecules with effects on cellular development and function
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
WO2006039400A2 (en) 2004-09-29 2006-04-13 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
ES2547866T3 (es) 2005-02-16 2015-10-09 The General Hospital Corporation Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina
US20060213667A1 (en) * 2005-03-28 2006-09-28 Mashburn Benny D Screen apparatus and method
JPWO2006115274A1 (ja) 2005-04-26 2008-12-18 味の素株式会社 骨髄赤血球前駆細胞分化促進剤
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
PT1931697E (pt) 2005-09-28 2010-12-06 Zymogenetics Inc Antagonistas de il-17a e il-17f e processos para a sua utilização
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
CN103432568A (zh) * 2005-11-23 2013-12-11 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
JP2009518422A (ja) 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
US7799787B2 (en) 2005-12-20 2010-09-21 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
EP2016423B1 (en) * 2006-01-20 2011-07-13 Beckman Coulter, Inc. Methods of detection of iron deficiency
EP1976377A4 (en) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
JP2009528375A (ja) 2006-02-28 2009-08-06 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
AU2007238705A1 (en) * 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
CA2652235A1 (en) * 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
WO2008011126A2 (en) * 2006-07-21 2008-01-24 Lyne Laboratories Liquid compositions of calcium acetate
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
JP5632582B2 (ja) 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
EP3320911B1 (en) 2006-12-18 2021-12-01 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
EP2111229B1 (en) * 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TW201940502A (zh) * 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
MX2009012934A (es) * 2007-06-01 2009-12-15 Wyeth Corp Metodos y composiciones para modular la actividad de bmp-10.
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009019504A1 (en) 2007-08-03 2009-02-12 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
WO2009035629A1 (en) 2007-09-13 2009-03-19 Ludwig Institute Of Cancer Research Method for modifying cellular immune response by modulating activin activity
US7960343B2 (en) * 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
BRPI0820387A2 (pt) 2007-11-21 2015-05-26 Amgen Inc Agentes de ligação de wise e epítopos
CA2718403A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
FR2930460B1 (fr) * 2008-04-25 2010-05-28 Valois Sas Distributeur de fragrance.
JP2011523357A (ja) 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
DK2318028T3 (da) 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
CA2729100C (en) 2008-06-26 2018-01-02 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US20110293526A1 (en) 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
MY159483A (en) 2008-11-26 2017-01-13 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
US8138142B2 (en) * 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
KR101836501B1 (ko) 2009-04-27 2018-03-08 노파르티스 아게 근육 성장을 증가시키기 위한 조성물 및 방법
CN104840944A (zh) 2009-06-08 2015-08-19 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
BR112012003232B1 (pt) 2009-08-13 2022-02-22 Acceleron Pharma Inc Uso de um polipeptídeo em conjunto com um ativador do receptor de eritropoetina para aumentar os níveis de célula vermelha no sangue ou tratar anemia
AU2010292203A1 (en) 2009-09-09 2012-04-12 Acceleron Pharma Inc. ActRIIb antagonists and dosing and uses thereof
US20110129469A1 (en) 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
EA202090053A3 (ru) 2011-10-17 2020-06-30 Акселерон Фарма, Инк. Способы и композиции для лечения неэффективного эритропоэза
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
AU2012321089B2 (en) 2011-10-28 2016-06-02 Paranta Biosciences Limited A method of treating mucus hypersecretion
EA201491231A8 (ru) 2011-12-19 2015-01-30 Амген Инк. Варианты полипептидов рецептора активина и их применение
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9663569B2 (en) 2012-06-14 2017-05-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
EP2868667B1 (en) 2012-07-02 2019-01-30 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient
US20150266950A1 (en) 2012-10-24 2015-09-24 Celgene Corporation Methods for treating anemia
EP3608419A1 (en) 2012-10-24 2020-02-12 Celgene Corporation Biomarker for use in treating anemia
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
WO2014093531A1 (en) 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin in strategies with stem cells
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
ES2692363T3 (es) 2013-03-14 2018-12-03 Translate Bio, Inc. Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3033358A2 (en) 2013-08-14 2016-06-22 Novartis AG Methods of treating sporadic inclusion body myositis
WO2015089575A1 (en) 2013-12-16 2015-06-25 Paranta Biosciences Limited Method of diagnosis and treatment
EP3094751A4 (en) 2014-01-14 2017-06-07 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
EP3100056A2 (en) 2014-01-27 2016-12-07 Novartis AG Biomarkers predictive of muscle atrophy, method and use
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
ES2845650T3 (es) 2014-04-18 2021-07-27 Acceleron Pharma Inc Procedimientos para aumentar los niveles de glóbulos rojos y tratar la drepanocitosis
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CN107074931A (zh) 2014-06-13 2017-08-18 圣塔玛丽亚生物疗法公司 经配制的受体多肽和相关方法

Also Published As

Publication number Publication date
AU2008216896A2 (en) 2011-07-14
TWI459963B (zh) 2014-11-11
SI2120999T1 (sl) 2012-12-31
JP2017071624A (ja) 2017-04-13
CN104548056B (zh) 2022-09-09
KR20190026047A (ko) 2019-03-12
HRP20120947T1 (hr) 2012-12-31
IL257848B (en) 2021-04-29
AU2008216896B2 (en) 2013-06-20
EA018221B1 (ru) 2013-06-28
MX368173B (es) 2019-09-23
BRPI0807506A2 (pt) 2013-07-30
JP6132861B2 (ja) 2017-05-24
TW201907953A (zh) 2019-03-01
KR20210082540A (ko) 2021-07-05
AR065289A1 (es) 2009-05-27
TW201808334A (zh) 2018-03-16
JP2020176139A (ja) 2020-10-29
CN101687016A (zh) 2010-03-31
CA2913992C (en) 2019-05-21
KR20160129095A (ko) 2016-11-08
TR200906329T1 (tr) 2010-01-21
CA2677605C (en) 2016-01-19
IL257848A (en) 2018-04-30
ES2756725T3 (es) 2020-04-27
TWI606062B (zh) 2017-11-21
CN104548056A (zh) 2015-04-29
EP2481415B1 (en) 2019-09-11
ES2394123T3 (es) 2013-01-22
TW201934141A (zh) 2019-09-01
JP5574711B2 (ja) 2014-08-20
DK2120999T3 (da) 2012-12-03
CN101687016B (zh) 2014-12-31
US20170190784A1 (en) 2017-07-06
WO2008100384A3 (en) 2008-12-11
CA2913992A1 (en) 2008-08-21
TW202140531A (zh) 2021-11-01
IL200242A0 (en) 2010-04-29
HK1137366A1 (en) 2010-07-30
US20090142333A1 (en) 2009-06-04
IL200242B (en) 2018-03-29
TWI525102B (zh) 2016-03-11
EP2120999B1 (en) 2012-08-29
EA201690994A1 (ru) 2016-09-30
EP2484372A1 (en) 2012-08-08
US8173601B2 (en) 2012-05-08
JP2018162312A (ja) 2018-10-18
RS52535B (en) 2013-04-30
TWI667038B (zh) 2019-08-01
JP2013224317A (ja) 2013-10-31
TW201500371A (zh) 2015-01-01
KR20200054317A (ko) 2020-05-19
US9572865B2 (en) 2017-02-21
KR20180083967A (ko) 2018-07-23
BRPI0807506B1 (pt) 2022-02-15
CA3039330A1 (en) 2008-08-21
EA025371B1 (ru) 2016-12-30
JP2010518079A (ja) 2010-05-27
EP2120999A2 (en) 2009-11-25
EP2481415A1 (en) 2012-08-01
KR101670417B1 (ko) 2016-11-10
PL2120999T3 (pl) 2013-01-31
KR20150115965A (ko) 2015-10-14
PT2120999E (pt) 2012-12-10
CA2677605A1 (en) 2008-08-21
TW201615660A (zh) 2016-05-01
ME02333B (me) 2013-04-30
JP2015091870A (ja) 2015-05-14
MX2009008510A (es) 2010-01-15
EA200970747A1 (ru) 2010-02-26
AU2008216896A1 (en) 2008-08-21
TW200900076A (en) 2009-01-01
WO2008100384A2 (en) 2008-08-21
CY1113963T1 (el) 2016-07-27
KR20100014850A (ko) 2010-02-11
IL281715A (en) 2021-05-31
US20210261682A1 (en) 2021-08-26
KR101672156B1 (ko) 2016-11-02
US20130004489A1 (en) 2013-01-03
CN104189889A (zh) 2014-12-10
CA3039330C (en) 2021-11-09

Similar Documents

Publication Publication Date Title
EA201300116A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
IN2012DN02766A (ru)
EA201691260A1 (ru) ВАРИАНТЫ, ПРОИСХОДЯЩИЕ ИЗ ActRIIB, И ИХ ПРИМЕНЕНИЕ
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA201590085A1 (ru) Антитела анти-egfr и их применение
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201100794A1 (ru) Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
EA200701995A1 (ru) Способы уменьшения кальцификации
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
DE602008000403D1 (de) Behandlung von medizinischen Implantaten, die kalkbeständig sind
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
EA201100874A1 (ru) Соединения для лечения рака
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
UA101961C2 (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form
EA201000141A1 (ru) Новые триазены для лечения рака
EA201591793A1 (ru) Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM